CClinicalTrials.gg
CompletedNCT02766985ROC-FSHDUpdated Apr 12, 2018

Rasch-analysis of Clinical Severity in FSHD

An observational study in Facioscapulohumeral Muscular Dystrophy, sponsored by University of Kansas Medical Center. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-12.

Sponsored by University of Kansas Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
44
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to make a standardized and scalable Rasch-built clinical severity scale to help in finding genetic and environmental modifiers of disease in Facioscapulohumeral muscular dystrophy (FSHD).

02

Conditions studied

  • Facioscapulohumeral Muscular Dystrophy

Keywords

  • FSHD
  • muscular dystrophy
03

In context

Muscular Dystrophies

548 studies on the registry are indexed under Muscular Dystrophies; 89 are open to participants now.

This study's enrollment of 44 is below the median of 69 across 179 observational studies indexed under Muscular Dystrophies.

Browse Muscular Dystrophies studies →

Lead sponsor

University of Kansas Medical Center is the lead sponsor of 483 studies on the registry; 113 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Particpants with genetically verified FSHD types 1 and 2.

Inclusion criteria

  • Genetic confirmation of FSHD (either FSHD-1 or FSHD-2)

Exclusion criteria

Exclusion Criteria:

  • Do not understand English
  • Unable to provide informed consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
44 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • FSHD

    Participants with FSHD-1 or FSHD-2. No intervention is given to participants. Participants will undergo series of tests and procedures in order to make a standardized and scalable Rasch-built clinical severity scale.

06

What researchers measure

Primary outcomes

  1. FSHD Clinical Severity Scale

    Measure severity of FSHD.

    Time frame: 1 day

Secondary outcomes

  1. Brooks scale

    Measures upper extremity function.Scores on the scale range from 1-6. A score of 1 means the person can elevate their arms above their head while arms remain straight. 6 means the person cannot elevate their arms to their mouth and do not have useful function of their hands.

    Time frame: 1 day

  2. Vignos scale

    Measures lower extremity function. Scores on the scale range from 1-10. A score of 1 means the person can walk and climb stairs without assistance. A score of 10 means the person is bedridden.

    Time frame: 1 day

  3. Iowa Oral Performance Instrument (IOPI)

    IOPI measures lip and tongue strength by measuring the amount of pressure a person can exert on the tool.

    Time frame: 1 day

  4. Manual muscle testing

    Measure person's range of motion. Scored on a scale with range of 0-5. Score of 0 means no movement. Score of 5 means the person has a full range of movement.

    Time frame: 1 day

  5. Quantitative strength testing

    Time frame: 1 day

  6. Functional testing

    Time frame: 1 day

  7. Reparatory function testing

    Time frame: 1 day

  8. Patient-reported outcome

    Time frame: 1 day

07

Study locations

2 sites
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02766985
Lead sponsor
University of Kansas Medical Center
Collaborators
National Institutes of Health (NIH)
Responsible party
Sponsor
First posted
May 10, 2016
Start date
Mar 2016
Primary completion
Apr 18, 2017
Completion
Apr 18, 2017
Last update
Apr 12, 2018

Study contacts

Jeffrey Statland, MD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion